MX350230B - Vacunas anticancer de globo h y relacionadas con adyuvantes de glucolipido novedosos. - Google Patents

Vacunas anticancer de globo h y relacionadas con adyuvantes de glucolipido novedosos.

Info

Publication number
MX350230B
MX350230B MX2014004316A MX2014004316A MX350230B MX 350230 B MX350230 B MX 350230B MX 2014004316 A MX2014004316 A MX 2014004316A MX 2014004316 A MX2014004316 A MX 2014004316A MX 350230 B MX350230 B MX 350230B
Authority
MX
Mexico
Prior art keywords
globo
ssea
immunogenic
immunogenic compositions
compositions
Prior art date
Application number
MX2014004316A
Other languages
English (en)
Inventor
Huey Wong Chi
Yi Wu Chung
Yu Alice
Yu John
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of MX350230B publication Critical patent/MX350230B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001173—Globo-H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a composiciones inmunogénicas, vacunas de cáncer y métodos para tratar cáncer. Se proporcionan composiciones que comprenden: (a) un glucano tal como Globo H o un fragmento inmunogénico del mismo, en donde el glucano está conjugado con una proteína portadora mediante un enlazador tal como para-nitrofenilo; y (b) un adyuvante que comprende glucolípido capaz de enlazar CDId sobre una célula dendritica, tal como un derivado de a-galactosil-ceramida, en donde la composición inmunogénica induce una respuesta inmune que induce un nivel relativo más alto de anticuerpos de isotipo IgG como es comparado con los anticuerpos de isotipo IgM. Se proporcionan composiciones inmunogénicas que comprenden el material de reacción cruzada de toxina de difteria de proteína portadora 197 (DT-CRM 197) y el adyuvante C34. Los anticuerpos generados por las composiciones inmunogénicas divulgadas en la presente además neutralizan por lo menos uno de los antígenos Globo H, antígeno embriónico específico de etapa-3 (SSEA-3) y antígeno embriónico específico de etapa-4 (SSEA-4). Terapias contra células madre de cáncer de seno que comprenden composiciones inmunogénicas que comprenden Globo H, SSEA-3 o SSEA-4 conjugado con DT-CRM 197.
MX2014004316A 2008-06-16 2009-08-06 Vacunas anticancer de globo h y relacionadas con adyuvantes de glucolipido novedosos. MX350230B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6196808P 2008-06-16 2008-06-16
US12/485,546 US20090317411A1 (en) 2008-06-16 2009-06-16 Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment
PCT/US2009/004519 WO2010005598A1 (en) 2008-06-16 2009-08-06 Globo h and related anti-cancer vaccines with novel glycolipid adjuvants

Publications (1)

Publication Number Publication Date
MX350230B true MX350230B (es) 2017-08-30

Family

ID=41431519

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010013932A MX2010013932A (es) 2008-06-16 2009-08-06 Vacunas anticancer de globo h y relacionadas con adyuvantes de glucolipido novedosos.
MX2014004316A MX350230B (es) 2008-06-16 2009-08-06 Vacunas anticancer de globo h y relacionadas con adyuvantes de glucolipido novedosos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2010013932A MX2010013932A (es) 2008-06-16 2009-08-06 Vacunas anticancer de globo h y relacionadas con adyuvantes de glucolipido novedosos.

Country Status (11)

Country Link
US (4) US20090317411A1 (es)
EP (2) EP2303286A4 (es)
JP (4) JP2011524375A (es)
KR (1) KR20110031949A (es)
CN (1) CN102065868A (es)
AU (2) AU2009268937A1 (es)
CA (2) CA2728344A1 (es)
ES (1) ES2570630T3 (es)
MX (2) MX2010013932A (es)
NZ (1) NZ590140A (es)
WO (2) WO2010005735A2 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
CA2728574C (en) * 2008-06-16 2020-10-20 Academia Sinica Cancer diagnosis based on levels of antibodies against globo h and its fragments
CA2728344A1 (en) * 2008-06-16 2010-01-14 Academia Sinica Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment
WO2010009271A2 (en) 2008-07-15 2010-01-21 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
TW201406389A (zh) 2010-05-03 2014-02-16 Dev Center Biotechnology 多醣體與大腸桿菌熱不穩定腸毒素之共軛物，其用途及製法
NZ604089A (en) 2010-06-11 2015-03-27 Sloan Kettering Inst Cancer Multivalent glycopeptide constructs and uses thereof
PT2608796T (pt) * 2010-08-05 2019-02-25 Seattle Genetics Inc Inibição de fucosilação de proteínas in vivo utilizando análogos de fucose
GB201013767D0 (en) * 2010-08-17 2010-09-29 Isis Innovation Identification of ligands and their use
US20120288525A1 (en) 2011-05-11 2012-11-15 Chakravarty Sumana Pharmaceutical compositions comprising attenuated plasmodium sporozoites and glycolipid adjuvants
JP6187939B2 (ja) * 2012-03-08 2017-08-30 学校法人産業医科大学 がんの悪性度の試験方法、ならびに多能性を有する造腫瘍細胞およびその調製方法
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
EP2885311B1 (en) 2012-08-18 2020-01-01 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US9547009B2 (en) 2012-08-21 2017-01-17 Academia Sinica Benzocyclooctyne compounds and uses thereof
US10350228B2 (en) 2012-08-23 2019-07-16 Seattle Genetics, Inc. Treatment of sickle cell disease and inflammatory conditions
SG11201505301XA (en) * 2013-01-04 2015-08-28 Obi Pharma Inc Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
EP2993182B1 (en) 2013-05-02 2020-10-14 National Institute of Advanced Industrial Science and Technology Immunity inducer for saccharide antigens
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
WO2014210564A1 (en) * 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
GB201313352D0 (en) 2013-07-26 2013-09-11 Isis Innovation Identification of peptide ligands
JP6486368B2 (ja) 2013-09-06 2019-03-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
AU2014391422A1 (en) 2013-09-17 2015-12-17 Obi Pharma, Inc. Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
CA2937123A1 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2016114819A1 (en) * 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
EP3119432B1 (en) 2014-03-19 2020-01-08 MacKay Medical Foundation the Presbyterian Church in Taiwan MacKay Memorial Hospital Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
JP6562942B2 (ja) 2014-03-27 2019-08-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 反応性標識化合物およびその使用
EP3662928A1 (en) 2014-04-10 2020-06-10 OBI Pharma Inc. Antibodies binding to tumour associated carbohydrate antigens, pharmaceutical compositions and uses thereof
KR20230033737A (ko) 2014-05-27 2023-03-08 아카데미아 시니카 증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
CA2950440A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-her2 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR20240096599A (ko) 2014-05-27 2024-06-26 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
JP7063538B2 (ja) 2014-05-28 2022-05-09 アカデミア シニカ 抗ＴＮＦα糖操作抗体群およびその使用
GB201414021D0 (en) * 2014-08-07 2014-09-24 Nascient Ltd Biological materials and uses thereof
WO2016029071A1 (en) 2014-08-22 2016-02-25 Academia Sinica Novel glycan conjugates and use thereof
US9879042B2 (en) 2014-09-08 2018-01-30 Academia Sinica Human iNKT cell activation using glycolipids
WO2016044164A1 (en) * 2014-09-15 2016-03-24 Wayne State University Novel synthetic anticancer, antifungal, and antibacterial vaccines
SG11201702037SA (en) * 2014-09-15 2017-04-27 Obi Pharma Inc Immunogenic/therapeutic glycoconjugate compositions and uses thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
KR102691114B1 (ko) 2015-01-24 2024-08-01 아카데미아 시니카 신규한 글리칸 콘주게이트 및 이를 사용하는 방법
AU2016209056B2 (en) * 2015-01-24 2021-01-28 Academia Sinica Cancer markers and methods of use thereof
ES2901173T3 (es) 2015-01-30 2022-03-21 Academia Sinica Composiciones y procedimientos relacionados con glicoformas universales para una eficacia de anticuerpos anti-SSEA4 mejorada
CN105067813A (zh) * 2015-07-23 2015-11-18 丁晓昆 一种快速检测t-合酶活性的方法
EP3344806A4 (en) * 2015-09-04 2019-03-20 OBI Pharma, Inc. GLYCAN NETWORKS AND METHODS OF USE
KR20180114210A (ko) 2016-03-08 2018-10-17 아카데미아 시니카 N-글리칸의 모듈 합성 방법 및 그의 어레이
AU2017239637A1 (en) 2016-03-29 2018-11-15 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
CN109379889A (zh) * 2016-04-22 2019-02-22 台湾浩鼎生技股份有限公司 通过经由globo系列抗原的免疫激活或免疫调节的癌症免疫疗法
BR112019001656A2 (pt) * 2016-07-27 2019-05-28 Obi Pharma Inc composição, composição farmacêutica, vacina, método para induzir anticorpos em um indivíduo, método para tratar câncer em um paciente necessitando do mesmo e método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo
TWI786054B (zh) 2016-07-29 2022-12-11 台灣浩鼎生技股份有限公司 人類抗體、醫藥組合物、及其方法
US10538592B2 (en) 2016-08-22 2020-01-21 Cho Pharma, Inc. Antibodies, binding fragments, and methods of use
TW201825522A (zh) * 2016-09-23 2018-07-16 張志隆 抗-globo h 抗體
WO2018094414A1 (en) * 2016-11-21 2018-05-24 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
WO2019217951A1 (en) * 2018-05-11 2019-11-14 Obi Pharma Inc. Method for predicting human immune response
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
US11958863B2 (en) 2018-11-02 2024-04-16 Siemens Healthcare Diagnostics Inc. Binding competitors for use in macrophilin-binding pharmaceutical assays and methods of use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544952B1 (en) * 1994-03-15 2003-04-08 Sloan-Kettering Institute For Cancer Research Synthesis of glycoconjugates of the globo-H epitope and uses thereof
US20040126381A1 (en) * 1996-04-23 2004-07-01 Xin-Xing Gu Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella
CA2286798C (en) * 1997-04-16 2014-01-07 Sloan-Kettering Institute For Cancer Research Alpha-o-linked glycoconjugates with clustered(2,6)-st epitopes, methods of preparation and uses thereof
AU2001241783A1 (en) * 2000-02-29 2001-09-12 Sloan-Kettering Institute For Cancer Research Affinity matrix bearing tumor-associated antigens
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
EP2263465A1 (en) 2001-07-06 2010-12-22 Sloan-Kettering Institute for Cancer Research Polyvalent conjugate vaccine for cancer
JP2005500336A (ja) * 2001-07-25 2005-01-06 ニューヨーク・ユニバーシティ 感染および癌に対するワクチンのためのアジュバントとしてのグリコシルセラミドの使用
US7132101B2 (en) * 2002-02-27 2006-11-07 Duquesne University Of The Holy Ghost Compositions and methods for eliciting an immune response to gram-negative bacterial infections
US20060116331A1 (en) * 2002-09-27 2006-06-01 Biomira, Inc. Glycosylceramide analogues
US20060035267A1 (en) * 2003-04-09 2006-02-16 Livingston Philip O Optimal polyvalent vaccine for cancer
GB0313916D0 (en) * 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
WO2006068758A2 (en) * 2004-11-19 2006-06-29 The Scripps Research Institute Detection, prevention and treatment of breast cancer
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
CA2591232C (en) 2004-12-28 2014-10-21 The Rockefeller University Glycolipids and analogues thereof as antigens for nk t cells
US7923013B2 (en) 2004-12-28 2011-04-12 The Rockefeller University Glycolipids and analogues thereof as antigens for NKT cells
KR100764678B1 (ko) * 2005-07-13 2007-10-09 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
CA2655947C (en) * 2006-06-30 2016-08-02 The Scripps Research Institute Compositions comprising nkt cell agonist compounds and methods of use
CN101225383B (zh) * 2007-01-15 2011-10-12 燕秋 用于抑制LeY糖抗原合成的岩藻糖基转移酶Ⅰ和Ⅳ的RNA干涉序列及重组干涉质粒
EP2112930B1 (en) * 2007-02-21 2017-01-11 Vaccinex, Inc. Modulation of nkt cell activity with antigen-loaded cdid molecules
GB0703369D0 (en) * 2007-02-21 2007-03-28 Health Prot Agency Compositions Comprising Capsular Polysaccharides and Their Use as Vaccines
TW200911274A (en) * 2007-04-13 2009-03-16 Academia Sinica Alpha-galatosyl ceramide analogs and their use as immunotherapies
CA2688268A1 (en) * 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
CA2728344A1 (en) * 2008-06-16 2010-01-14 Academia Sinica Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment
US8383767B2 (en) * 2008-06-27 2013-02-26 Academia Sinica Immunogenic protein carrier containing an antigen presenting cell binding domain and a cysteine-rich domain
US7928077B2 (en) * 2008-07-11 2011-04-19 Academia Sinica Alpha-galactosyl ceramide analogs and their use as immunotherapies

Also Published As

Publication number Publication date
EP2303286A2 (en) 2011-04-06
JP2016020363A (ja) 2016-02-04
WO2010005735A3 (en) 2010-03-18
US20090317411A1 (en) 2009-12-24
JP5795655B2 (ja) 2015-10-14
CA2728341A1 (en) 2010-01-14
KR20110031949A (ko) 2011-03-29
MX2010013932A (es) 2013-03-01
ES2570630T3 (es) 2016-05-19
CA2728341C (en) 2019-07-02
AU2009269127A1 (en) 2010-01-14
JP2011524375A (ja) 2011-09-01
JP6151319B2 (ja) 2017-06-21
US8268969B2 (en) 2012-09-18
AU2009268937A1 (en) 2010-01-14
EP2310047B1 (en) 2016-03-30
AU2009269127B2 (en) 2013-12-05
JP5628158B2 (ja) 2014-11-19
US9603913B2 (en) 2017-03-28
CN102065868A (zh) 2011-05-18
CA2728344A1 (en) 2010-01-14
US20150273034A1 (en) 2015-10-01
JP2011524417A (ja) 2011-09-01
WO2010005598A1 (en) 2010-01-14
JP2014144958A (ja) 2014-08-14
NZ590140A (en) 2012-07-27
US9028836B2 (en) 2015-05-12
WO2010005735A2 (en) 2010-01-14
EP2310047A1 (en) 2011-04-20
US20100136042A1 (en) 2010-06-03
EP2303286A4 (en) 2011-12-28
US20120328646A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
MX350230B (es) Vacunas anticancer de globo h y relacionadas con adyuvantes de glucolipido novedosos.
MX2011009437A (es) Vacunas contra cancer a base de de celulas presentadoras de antigeno.
MX2011009438A (es) Anticuerpos anti-cd40 y usos de los mismos.
MX2012003058A (es) Vacunas dirigidas a celulas de langerhans.
GB0428394D0 (en) Saccharide conjugate vaccines
SG162817A1 (en) Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
MX2023009362A (es) Vacunas de conjugado multivalente con polisacaridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas.
MX2022014125A (es) Anticuerpos y conjugados de los mismos.
MX2007002787A (es) Adyuvante de glicosilceramida para antigenos de sacarido.
EA035991B9 (ru) Новый полисахарид и его применения
MX2013001527A (es) Nuevas vacunas adyuvantes en base a adyuvantes de orientacion para anticuerpos directamente hacia celulas presentadoras de antigenos.
GB2434367A (en) Improved vaccines
EA201070329A1 (ru) Векторы и конструкции для доставки гриппозного антигена
PH12015501519A1 (en) Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
MX2007015950A (es) Inmunoterapeuticos multivalentes de transporte y ampliacion para carcinoma.
MX2010001237A (es) Nuevos anticuerpos.
MX2011009359A (es) Conjugados hapteno-portador con toxinas bacterianas que tienen un peptido señal como portador, y su uso en composiciones inmunogenas.
WO2009114085A3 (en) Allogeneic cancer cell-based immunotherapy
MX2019006104A (es) Conjugados inmunogenicos y uso de los mismos.
MX2022005884A (es) Tecnologías de conjugación dirigida.
MX2023010813A (es) Anticuerpos anti-alpp/alppl2 y conjugados de anticuerpo-farmaco.
WO2012138774A3 (en) Methods of improving vaccine immunogenicity
WO2022066965A3 (en) Immunotherapy targeting sox2 antigens
TR200704213T2 (tr) İnterleukin-2'nin reseptörüne bağlanmasını önleyebilen otoantikorlar üretmek için immünoterapötik formülasyonlar, bunların kanser tedavisinde kullanımı.
MX2009008754A (es) Anticuerpos novedosos contra igf-1r.